Dynavax will develop candidates that signal through receptors of the immune system.
Dynavax Technologies has been awarded $17 million to develop novel vaccine adjuvant candidates. This five-year NIAID contract supports adjuvant development for anthrax, as well as other disease models.
Dynavax will use its immunostimulatory sequences technology using toll-like receptor 9 agonists as vaccine adjuvants. “The funding from this contract as well as from the NIH grants for our Universal Flu vaccine program enables us to devote significant resources to advance our vaccine programs into clinical development,” states Dino Dina, M.D., president and CEO.
